2006 Molecular Therapeutics of Cancer Gordon Research Conference

描述（由申请人提供）：自1978年以来，每年举行一次的戈登癌症分子治疗研究会议（最初以实验和临床癌症化疗的名义），为新型药物，药物靶点以及新型疗法的临床前和临床开发的介绍和讨论提供了高度互动的论坛。 与会者代表了制药行业、生物技术公司以及临床和学术机构的各种利益。 该会议旨在通过介绍新颖的未发表的工作来促进人类癌症治疗的进步，并专注于将这些进步带到患者护理服务中的方式。 会议场地的非正式性，再加上GRC活跃和广泛讨论的传统，为来自学术界，工业界和临床竞技场的个人之间的互动提供了一个独特的机会。 2006年会议将继续在癌症治疗的最前沿讨论新的想法、问题和解决办法，重点是尚未在更大的国家和国际会议上提出的目标和战略。 主题将包括：靶向肿瘤中的脂肪生成途径;细胞周期检查点调控; BRCA 1/2缺陷肿瘤的靶向治疗;发育基因调控（Hedgehog、Wnt、Notch）;干细胞对治疗反应的影响;解决基因和siRNA递送问题;蛋白磷酸酶作为治疗靶点、分子预后和新型治疗技术（纳米技术和成像）。

DESCRIPTION (provided by applicant): This Gordon Research Conference on Molecular Therapeutics of Cancer, held annually since 1978 (initially under the name of Chemotherapy of Experimental and Clinical Cancer), provides a highly interactive forum for the presentation and discussion of novel drugs, drug targets and the preclinical and clinical development of novel therapeutics. Meeting participants represent a diverse range of interests, spanning the pharmaceutical industry, biotechnology companies, and clinical and academic institutions. The meeting seeks to promote advancements in the treatment of human cancer through the presentation of novel, unpublished work, and to focus on the ways these advancements can be brought to the service of patient care. The informality of the meeting venue, coupled with the GRC tradition of lively and extensive discussions, provides a unique opportunity for interactions between individuals from academia, industry and the clinical arena. The 2006 meeting will continue the trend of addressing new ideas, questions and solutions at the forefront of cancer therapy focusing on targets and strategies that have yet to be presented at larger national and international meetings. Topics will include: targeting the lipogenic pathways in tumors; cell cycle checkpoint regulation; targeting therapy to BRCA1/2 defective tumors; developmental gene regulation (Hedgehog, Wnt, Notch); impact of stem cells on therapeutic response; solving problems in gene and siRNA delivery; protein phosphatases as therapeutic targets, molecular prognosis, and novel therapeutic technologies (nanotechnology and imaging).